{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T05:44:02Z","timestamp":1792043042344,"version":"4.4.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastrointest Canc"],"DOI":"10.1007\/s12029-026-01614-8","type":"journal-article","created":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:44:26Z","timestamp":1792039466000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Neoadjuvant and Perioperative Immunotherapy for Resectable Esophageal Squamous Cell Carcinoma: Current Evidence, Endpoints, and Clinical Integration"],"prefix":"10.1007","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1994-4795","authenticated-orcid":false,"given":"Tamotsu","family":"Sagawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Hirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Nagashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koshi","family":"Fujikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"1614_CR1","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1007\/s10388-023-00993-2","volume":"20","author":"Y Kitagawa","year":"2023","unstructured":"Kitagawa Y, Ishihara R, Ishikawa H, et al. Esophageal cancer practice guidelines 2022 edited by the Japan Esophageal Society: part 1. Esophagus. 2023;20:343\u201372. https:\/\/doi.org\/10.1007\/s10388-023-00993-2.","journal-title":"Esophagus"},{"key":"1614_CR2","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1245\/s10434-011-2049-9","volume":"19","author":"N Ando","year":"2012","unstructured":"Ando N, Kato H, Igaki H, et al. A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907). Ann Surg Oncol. 2012;19:68\u201374. https:\/\/doi.org\/10.1245\/s10434-011-2049-9.","journal-title":"Ann Surg Oncol"},{"key":"1614_CR3","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(24)00745-1","volume":"404","author":"K Kato","year":"2024","unstructured":"Kato K, Machida R, Ito Y, et al. Doublet chemotherapy, triplet chemotherapy, or doublet chemotherapy combined with radiotherapy as neoadjuvant treatment for locally advanced oesophageal cancer (JCOG1109 NExT): a randomized, controlled, open-label, phase 3 trial. Lancet. 2024;404:55\u201366. https:\/\/doi.org\/10.1016\/S0140-6736(24)00745-1.","journal-title":"Lancet"},{"key":"1614_CR4","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MCCM, van Lanschot JJB, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074\u201384. https:\/\/doi.org\/10.1056\/NEJMoa1112088.","journal-title":"N Engl J Med"},{"key":"1614_CR5","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1200\/JCO.20.03614","volume":"39","author":"BM Eyck","year":"2021","unstructured":"Eyck BM, van Lanschot JJB, Hulshof MCCM, et al. Ten-year outcome of neoadjuvant chemoradiotherapy plus surgery for esophageal cancer: the randomized controlled CROSS trial. J Clin Oncol. 2021;39:1995\u20132004. https:\/\/doi.org\/10.1200\/JCO.20.03614.","journal-title":"J Clin Oncol"},{"key":"1614_CR6","doi-asserted-by":"publisher","first-page":"2796","DOI":"10.1200\/JCO.2018.79.1483","volume":"36","author":"H Yang","year":"2018","unstructured":"Yang H, Liu H, Chen Y, et al. Neoadjuvant chemoradiotherapy followed by surgery versus surgery alone for locally advanced squamous cell carcinoma of the esophagus (NEOCRTEC5010): a phase III multicenter, randomized, open-label clinical trial. J Clin Oncol. 2018;36:2796\u2013803. https:\/\/doi.org\/10.1200\/JCO.2018.79.1483.","journal-title":"J Clin Oncol"},{"key":"1614_CR7","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1001\/jamasurg.2021.2373","volume":"156","author":"H Yang","year":"2021","unstructured":"Yang H, Liu H, Chen Y, et al. Long-term efficacy of neoadjuvant chemoradiotherapy plus surgery for the treatment of locally advanced esophageal squamous cell carcinoma: the NEOCRTEC5010 randomized clinical trial. JAMA Surg. 2021;156:721\u20139. https:\/\/doi.org\/10.1001\/jamasurg.2021.2373.","journal-title":"JAMA Surg"},{"key":"1614_CR8","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.annonc.2022.10.508","volume":"34","author":"H Tang","year":"2023","unstructured":"Tang H, Wang H, Fang Y, et al. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial. Ann Oncol. 2023;34:163\u201372. https:\/\/doi.org\/10.1016\/j.annonc.2022.10.508.","journal-title":"Ann Oncol"},{"key":"1614_CR9","doi-asserted-by":"publisher","first-page":"2549","DOI":"10.1038\/s41591-024-03064-w","volume":"30","author":"J Qin","year":"2024","unstructured":"Qin J, Xue L, Hao A, et al. Neoadjuvant chemotherapy with or without camrelizumab in resectable esophageal squamous cell carcinoma: the randomized phase 3 ESCORT-NEO\/NCCES01 trial. Nat Med. 2024;30:2549\u201357. https:\/\/doi.org\/10.1038\/s41591-024-03064-w.","journal-title":"Nat Med"},{"key":"1614_CR10","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1002\/cac2.12604","volume":"44","author":"Y Zheng","year":"2024","unstructured":"Zheng Y, Liang G, Yuan D, et al. Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial. Cancer Commun (Lond). 2024;44:1214\u201327. https:\/\/doi.org\/10.1002\/cac2.12604.","journal-title":"Cancer Commun (Lond)"},{"issue":"16suppl","key":"1614_CR11","doi-asserted-by":"publisher","first-page":"4076","DOI":"10.1200\/JCO.2025.43.16_suppl.4076","volume":"43","author":"Y Zheng","year":"2025","unstructured":"Zheng Y, Liu X, Liang G, et al. An interim analysis of phase III study on neoadjuvant chemotherapy versus perioperative toripalimab plus neoadjuvant chemotherapy for locally advanced esophageal squamous cell carcinoma: HCHTOG1909. J Clin Oncol. 2025;43(16suppl):4076. https:\/\/doi.org\/10.1200\/JCO.2025.43.16_suppl.4076. [abstract].","journal-title":"J Clin Oncol"},{"key":"1614_CR12","doi-asserted-by":"publisher","first-page":"9676","DOI":"10.1038\/s41467-025-64660-z","volume":"16","author":"P Wang","year":"2025","unstructured":"Wang P, Chen Y, Wang F, et al. Camrelizumab plus chemotherapy versus chemoradiotherapy as neoadjuvant therapy for resectable esophageal squamous cell carcinoma: phase 2 randomized trial (REVO). Nat Commun. 2025;16:9676. https:\/\/doi.org\/10.1038\/s41467-025-64660-z.","journal-title":"Nat Commun"},{"issue":"4suppl","key":"1614_CR13","doi-asserted-by":"publisher","first-page":"LBA329","DOI":"10.1200\/JCO.2025.43.4_suppl.LBA329","volume":"43","author":"X Leng","year":"2025","unstructured":"Leng X, He W, Lyu J, et al. Preliminary results from the multicenter, randomized phase III trial (SCIENCE): comparing chemotherapy plus sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy for neoadjuvant treatment in resectable locally advanced esophageal squamous cell carcinoma. J Clin Oncol. 2025;43(4suppl):LBA329. https:\/\/doi.org\/10.1200\/JCO.2025.43.4_suppl.LBA329. [abstract].","journal-title":"J Clin Oncol"},{"issue":"17suppl","key":"1614_CR14","doi-asserted-by":"publisher","first-page":"LBA4082","DOI":"10.1200\/JCO.2026.44.17_suppl.LBA4082","volume":"44","author":"X Leng","year":"2026","unstructured":"Leng X, Gong L, Lyu J, et al. Pathological complete response and ctDNA analyses in SCIENCE: results from a randomized, phase III trial of neoadjuvant chemotherapy plus sintilimab and chemoradiotherapy plus sintilimab versus chemoradiotherapy in resectable locally advanced esophageal squamous cell carcinoma. J Clin Oncol. 2026;44(17suppl):LBA4082. https:\/\/doi.org\/10.1200\/JCO.2026.44.17_suppl.LBA4082. [abstract].","journal-title":"J Clin Oncol"},{"key":"1614_CR15","doi-asserted-by":"publisher","first-page":"105191","DOI":"10.1016\/j.critrevonc.2026.105191","volume":"221","author":"C Yu","year":"2026","unstructured":"Yu C, Zhang D, Chen C, et al. Neoadjuvant immunotherapy for resectable esophageal cancer: Research progress and clinical perspectives. Crit Rev Oncol Hematol. 2026;221:105191. https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105191.","journal-title":"Crit Rev Oncol Hematol"},{"key":"1614_CR16","doi-asserted-by":"publisher","first-page":"1825905","DOI":"10.3389\/fimmu.2026.1825905","volume":"17","author":"Y Ye","year":"2026","unstructured":"Ye Y, Zhang L, Yang Z, et al. Efficacy and safety of neoadjuvant chemotherapy with immunotherapy versus chemotherapy alone in esophageal squamous cell carcinoma: a meta-analysis based on randomized controlled trials. Front Immunol. 2026;17:1825905. https:\/\/doi.org\/10.3389\/fimmu.2026.1825905.","journal-title":"Front Immunol"},{"key":"1614_CR17","doi-asserted-by":"publisher","unstructured":"Ghalehtaki R, Shariati A, Fanihagh T, Moradi Z, Moradi N. Concurrent versus sequential immune checkpoint inhibition in the neoadjuvant treatment of resectable esophageal squamous cell carcinoma: a systematic review and meta-analysis. Clin Transl Radiat Oncol Published online September. 2026;10. https:\/\/doi.org\/10.1016\/j.ctro.2026.101289.","DOI":"10.1016\/j.ctro.2026.101289"},{"issue":"6","key":"1614_CR18","doi-asserted-by":"publisher","first-page":"679","DOI":"10.21037\/jtd-2026-0508","volume":"18","author":"Y Yan","year":"2026","unstructured":"Yan Y, Lyu J, Chen Y, Leng X. Response-adapted perioperative therapy for resectable esophageal cancer in the immunotherapy era: a narrative review. J Thorac Dis. 2026;18(6):679. https:\/\/doi.org\/10.21037\/jtd-2026-0508.","journal-title":"J Thorac Dis"},{"key":"1614_CR19","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.21037\/atm-21-5381","volume":"9","author":"Z Zhang","year":"2021","unstructured":"Zhang Z, Hong ZN, Xie S, et al. Neoadjuvant sintilimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: a single-arm, single-center, phase 2 trial (ESONICT-1). Ann Transl Med. 2021;9:1623. https:\/\/doi.org\/10.21037\/atm-21-5381.","journal-title":"Ann Transl Med"},{"key":"1614_CR20","doi-asserted-by":"publisher","first-page":"e004291","DOI":"10.1136\/jitc-2021-004291","volume":"10","author":"J Liu","year":"2022","unstructured":"Liu J, Yang Y, Liu Z, et al. Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma. J Immunother Cancer. 2022;10:e004291. https:\/\/doi.org\/10.1136\/jitc-2021-004291.","journal-title":"J Immunother Cancer"},{"key":"1614_CR21","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.jtcvs.2023.08.056","volume":"167","author":"Y Yang","year":"2024","unstructured":"Yang Y, Liu J, Liu Z, et al. Two-year outcomes of clinical N2-3 esophageal squamous cell carcinoma after neoadjuvant chemotherapy and immunotherapy from the phase 2 NICE study. J Thorac Cardiovasc Surg. 2024;167:838\u2013e8471. https:\/\/doi.org\/10.1016\/j.jtcvs.2023.08.056.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"1614_CR22","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1038\/s41591-023-02469-3","volume":"29","author":"J Yin","year":"2023","unstructured":"Yin J, Yuan J, Li Y, et al. Neoadjuvant adebrelimab in locally advanced resectable esophageal squamous cell carcinoma: a phase 1b trial. Nat Med. 2023;29:2068\u201378. https:\/\/doi.org\/10.1038\/s41591-023-02469-3.","journal-title":"Nat Med"},{"key":"1614_CR23","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1016\/j.ccell.2024.09.008","volume":"42","author":"X Shang","year":"2024","unstructured":"Shang X, Xie Y, Yu J, et al. A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: the Keystone-001 trial. Cancer Cell. 2024;42:1747\u2013e17637. https:\/\/doi.org\/10.1016\/j.ccell.2024.09.008.","journal-title":"Cancer Cell"},{"key":"1614_CR24","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ejca.2020.11.039","volume":"144","author":"C Li","year":"2021","unstructured":"Li C, Zhao S, Zheng Y, et al. Preoperative pembrolizumab combined with chemoradiotherapy for oesophageal squamous cell carcinoma (PALACE-1). Eur J Cancer. 2021;144:232\u201341. https:\/\/doi.org\/10.1016\/j.ejca.2020.11.039.","journal-title":"Eur J Cancer"},{"key":"1614_CR25","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/s41392-025-02477-4","volume":"10","author":"C Li","year":"2025","unstructured":"Li C, Han Y, Zhao S, et al. Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1\/2 trial (PALACE-2). Signal Transduct Target Ther. 2025;10:386. https:\/\/doi.org\/10.1038\/s41392-025-02477-4.","journal-title":"Signal Transduct Target Ther"},{"key":"1614_CR26","doi-asserted-by":"publisher","first-page":"e7076","DOI":"10.1002\/cam4.7076","volume":"13","author":"CE Gaber","year":"2024","unstructured":"Gaber CE, Sarker J, Abdelaziz AI, et al. Pathologic complete response in patients with esophageal cancer receiving neoadjuvant chemotherapy or chemoradiation: a systematic review and meta-analysis. Cancer Med. 2024;13:e7076. https:\/\/doi.org\/10.1002\/cam4.7076.","journal-title":"Cancer Med"},{"key":"1614_CR27","doi-asserted-by":"publisher","first-page":"znaf131","DOI":"10.1093\/bjs\/znaf131","volume":"112","author":"J Okui","year":"2025","unstructured":"Okui J, Nagashima K, Matsuda S, et al. Evaluation of pathological complete response as a surrogate endpoint for overall survival in resectable oesophageal cancer: integrated analysis of individual patient data from phase III trials. Br J Surg. 2025;112:znaf131. https:\/\/doi.org\/10.1093\/bjs\/znaf131.","journal-title":"Br J Surg"},{"issue":"2suppl","key":"1614_CR28","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1200\/JCO.2026.44.2_suppl.457","volume":"44","author":"T Yoshii","year":"2026","unstructured":"Yoshii T, Yokota T, Kato K, et al. Impact of pathological complete response after DCF neoadjuvant chemotherapy followed by surgery on survival in esophageal squamous cell carcinoma: a supplementary analysis of JCOG1109. J Clin Oncol. 2026;44(2suppl):457. https:\/\/doi.org\/10.1200\/JCO.2026.44.2_suppl.457. [abstract].","journal-title":"J Clin Oncol"},{"key":"1614_CR29","doi-asserted-by":"publisher","first-page":"znag012","DOI":"10.1093\/bjs\/znag012","volume":"113","author":"J Okui","year":"2026","unstructured":"Okui J, Matsuda S, Nagashima K, et al. Survival after pathological complete response following neoadjuvant chemotherapy versus chemoradiotherapy for oesophageal squamous cell carcinoma. Br J Surg. 2026;113:znag012. https:\/\/doi.org\/10.1093\/bjs\/znag012.","journal-title":"Br J Surg"},{"key":"1614_CR30","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.1016\/j.jtcvs.2020.09.042","volume":"162","author":"H Tang","year":"2021","unstructured":"Tang H, Jiang D, Zhang S, et al. Residual tumor characteristics of esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy. J Thorac Cardiovasc Surg. 2021;162:1632\u201341. https:\/\/doi.org\/10.1016\/j.jtcvs.2020.09.042.","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"2","key":"1614_CR31","doi-asserted-by":"publisher","first-page":"znae038","DOI":"10.1093\/bjs\/znae038","volume":"111","author":"J Okui","year":"2024","unstructured":"Okui J, Nagashima K, Matsuda S, et al. Recurrence-free survival as a surrogate endpoint for overall survival after neoadjuvant chemotherapy and surgery for oesophageal squamous cell carcinoma. Br J Surg. 2024;111(2):znae038. https:\/\/doi.org\/10.1093\/bjs\/znae038.","journal-title":"Br J Surg"},{"key":"1614_CR32","doi-asserted-by":"publisher","unstructured":"Zhao Y, Zhang R, Li Y, et al. CX3CR1\u2009+\u2009CD8+ cytotoxic T cells drive tumor killing in esophageal squamous cell carcinoma during neoadjuvant therapy. Nat Commun. Published online August. 2026;22. https:\/\/doi.org\/10.1038\/s41467-026-76959-6.","DOI":"10.1038\/s41467-026-76959-6"},{"key":"1614_CR33","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384:1191\u2013203. https:\/\/doi.org\/10.1056\/NEJMoa2032125.","journal-title":"N Engl J Med"},{"issue":"19","key":"1614_CR34","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.2217\/fon-2020-0189","volume":"16","author":"S Yamamoto","year":"2020","unstructured":"Yamamoto S, Kato K, Daiko H, et al. Feasibility study of nivolumab as neoadjuvant chemotherapy for locally esophageal carcinoma: FRONTiER (JCOG1804E). Future Oncol. 2020;16(19):1351\u20137. https:\/\/doi.org\/10.2217\/fon-2020-0189.","journal-title":"Future Oncol"},{"issue":"4suppl","key":"1614_CR35","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1200\/JCO.2022.40.4_suppl.286","volume":"40","author":"S Matsuda","year":"2022","unstructured":"Matsuda S, Yamamoto S, Kato K, et al. FRONTiER: a feasibility trial of nivolumab with neoadjuvant CF or DCF, FLOT therapy for locally advanced esophageal carcinoma (JCOG1804E)-short-term results for cohorts C and D. J Clin Oncol. 2022;40(4suppl):286. https:\/\/doi.org\/10.1200\/JCO.2022.40.4_suppl.286. [abstract].","journal-title":"J Clin Oncol"},{"issue":"2","key":"1614_CR36","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1093\/jjco\/hyad150","volume":"54","author":"R Kita","year":"2024","unstructured":"Kita R, Matsuda S, Nomura M, Japan Esophageal Oncology Group of the Japan Clinical Oncology Group, et al. Protocol digest of a randomized controlled Phase III study comparing surgery alone versus adjuvant nivolumab versus adjuvant S-1 for locally advanced oesophageal squamous cell carcinoma with no pathological complete response after neoadjuvant chemotherapy followed by curative esophagectomy: Japan Clinical Oncology Group study JCOG2206 (SUNRISE Trial). Jpn J Clin Oncol. 2024;54(2):212\u20136. https:\/\/doi.org\/10.1093\/jjco\/hyad150.","journal-title":"Jpn J Clin Oncol"},{"key":"1614_CR37","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1093\/jrr\/rraf029","volume":"66","author":"K Jingu","year":"2025","unstructured":"Jingu K, Nihei K, Ito Y, et al. Radiotherapy treatment planning for esophageal cancer: JASTRO guidelines 2024 for radiotherapy treatment planning. J Radiat Res. 2025;66:354\u201364. https:\/\/doi.org\/10.1093\/jrr\/rraf029.","journal-title":"J Radiat Res"},{"key":"1614_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.annonc.2025.09.008","volume":"37","author":"ESM van Aken","year":"2026","unstructured":"van Aken ESM, Devnani B, Prelaj A, et al. ESMO-ESTRO consensus statements on the safety of combining radiotherapy with immune checkpoint inhibitors, VEGF(R) inhibitors, or multitargeted tyrosine kinase inhibitors. Ann Oncol. 2026;37:17\u201332. https:\/\/doi.org\/10.1016\/j.annonc.2025.09.008.","journal-title":"Ann Oncol"},{"key":"1614_CR39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.radmp.2024.02.003","volume":"5","author":"Professional Committee of Radiation Oncology, China Anti-Cancer Association","year":"2024","unstructured":"Professional Committee of Radiation Oncology, China Anti-Cancer Association. Branch of Radiation Oncology, Chinese Medical Association; Branch of Radiation Oncology Treatment Physician, Chinese Medical Doctor Association. Expert consensus on radiotherapy combined with immunotherapy for esophageal cancer (2024 edition). Radiat Med Prot. 2024;5:59\u201367. https:\/\/doi.org\/10.1016\/j.radmp.2024.02.003.","journal-title":"Radiat Med Prot"},{"key":"1614_CR40","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/S1470-2045(18)30201-8","volume":"19","author":"BJ Noordman","year":"2018","unstructured":"Noordman BJ, Spaander MCW, Valkema R, et al. SANO study group. Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study. Lancet Oncol. 2018;19:965\u201374. https:\/\/doi.org\/10.1016\/S1470-2045(18)30201-8.","journal-title":"Lancet Oncol"},{"key":"1614_CR41","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.2967\/jnumed.118.224196","volume":"60","author":"MJ Valkema","year":"2019","unstructured":"Valkema MJ, Noordman BJ, Wijnhoven BPL, et al. Accuracy of 18F-FDG PET\/CT in predicting residual disease after neoadjuvant chemoradiotherapy for esophageal cancer. J Nucl Med. 2019;60:1553\u20139. https:\/\/doi.org\/10.2967\/jnumed.118.224196.","journal-title":"J Nucl Med"},{"key":"1614_CR42","doi-asserted-by":"publisher","first-page":"324","DOI":"10.2967\/jnmt.121.262151","volume":"49","author":"JH Schierz","year":"2021","unstructured":"Schierz JH, Sarikaya I, Wollina U, Unger L, Sarikaya A. Immune checkpoint inhibitor-related adverse effects and 18F-FDG PET\/CT findings. J Nucl Med Technol. 2021;49:324\u20139. https:\/\/doi.org\/10.2967\/jnmt.121.262151.","journal-title":"J Nucl Med Technol"},{"key":"1614_CR43","doi-asserted-by":"publisher","first-page":"e093538","DOI":"10.1136\/bmjopen-2024-093538","volume":"15","author":"X Wang","year":"2025","unstructured":"Wang X, Li C, Cao Y, et al. Neoadjuvant camrelizumab combined with chemoradiotherapy and watch-and-wait strategy versus neoadjuvant chemoradiotherapy followed by surgery in locally advanced oesophageal squamous cell carcinoma: study protocol of a randomized controlled trial (PALACE-3). BMJ Open. 2025;15:e093538. https:\/\/doi.org\/10.1136\/bmjopen-2024-093538.","journal-title":"BMJ Open"},{"issue":"4","key":"1614_CR44","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1470-2045(25)00027-0","volume":"26","author":"BJ van der Wilk","year":"2025","unstructured":"van der Wilk BJ, Eyck BM, Wijnhoven BPL, SANO Study Group, et al. Neoadjuvant chemoradiotherapy followed by active surveillance versus standard surgery for oesophageal cancer (SANO trial): a multicentre, stepped-wedge, cluster-randomised, non-inferiority, phase 3 trial. Lancet Oncol. 2025;26(4):425\u201336. https:\/\/doi.org\/10.1016\/S1470-2045(25)00027-0.","journal-title":"Lancet Oncol"},{"key":"1614_CR45","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1053\/j.gastro.2021.08.007","volume":"161","author":"K Kato","year":"2021","unstructured":"Kato K, Ito Y, Nozaki I, et al. Parallel-group controlled trial of surgery versus chemoradiotherapy in patients with stage I esophageal squamous cell carcinoma. Gastroenterology. 2021;161:1878\u2013e18862. https:\/\/doi.org\/10.1053\/j.gastro.2021.08.007.","journal-title":"Gastroenterology"}],"container-title":["Journal of Gastrointestinal Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01614-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01614-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12029-026-01614-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T04:44:41Z","timestamp":1792039481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12029-026-01614-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1614"],"URL":"https:\/\/doi.org\/10.1007\/s12029-026-01614-8","relation":{},"ISSN":["1941-6636"],"issn-type":[{"value":"1941-6636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"14 August 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable; this article is a review of previously published studies and does not contain any studies with human participants or animals performed by any of the authors.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"235"}}